Sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
mycophenolate	mycophenolate	O	O	OTHERS	I
mofetil	mofetil	O	O	OTHERS	I
for	for	O	O	O	O
calcineurin-free	calcineurin-free	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
.	.	O	O	O	O

Calcineurin	calcineurin	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
available	available	O	O	O	O
for	for	O	O	O	O
almost	almost	O	O	O	O
20	20	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
are	are	O	O	O	O
highly	highly	O	O	O	O
effective	effective	O	O	O	O
and	and	O	O	O	O
represent	represent	O	O	O	O
the	the	O	O	O	O
mainstay	mainstay	O	O	O	O
of	of	O	O	O	O
transplant	transplant	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
,	,	O	O	O	O
they	they	O	O	O	O
are	are	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
acute	acute	O	O	O	O
and	and	O	O	O	O
chronic	chronic	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Acute	acute	O	O	OTHERS	I
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
occurs	occurs	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
period	period	O	O	O	O
after	after	O	O	O	O
transplantation	transplantation	O	O	O	O
,	,	O	O	O	O
leads	leads	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
dialysis	dialysis	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
chronic	chronic	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
may	may	O	O	O	O
eventually	eventually	O	O	O	O
result	result	O	O	O	O
in	in	O	O	O	O
graft	graft	O	O	O	O
loss	loss	O	O	O	O
.	.	O	O	O	O

Acute	acute	O	O	O	O
and	and	O	O	O	O
chronic	chronic	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
becoming	becoming	O	O	O	O
more	more	O	O	O	O
common	common	O	O	O	O
as	as	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
marginal	marginal	O	O	O	O
kidneys	kidneys	O	O	O	O
for	for	O	O	O	O
transplantation	transplantation	O	O	O	O
increases	increases	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
recently	recently	O	O	O	O
available	available	O	O	O	O
immunosuppressive	immunosuppressive	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
mycophenolate	mycophenolate	O	O	OTHERS	I
mofetil	mofetil	O	O	OTHERS	I
and	and	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
rapamycin	rapamycin	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
have	have	O	O	O	O
no	no	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
agents	agents	O	O	O	O
has	has	O	O	O	O
led	led	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
paradigms	paradigms	O	O	O	O
of	of	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
paper	paper	O	O	O	O
reviews	reviews	O	O	O	O
the	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
trials	trials	O	O	O	O
that	that	O	O	O	O
have	have	O	O	O	O
investigated	investigated	O	O	O	O
these	these	O	O	O	O
new	new	O	O	O	O
approaches	approaches	O	O	O	O
to	to	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
.	.	O	O	O	O

